Skip to main content

Table 2 TALEN cell therapy clinical trials.

From: The clinical potential of gene editing as a tool to engineer cell-based therapeutics

Disease

Trial name

Phase

Cell type edited

Target patients

Status

Sponsor

Countries

CT number

Cancer

Study of UCART19 in pediatric patients with relapsed/refractory B acute lymphoblastic leukemia (PALL)

I

Allogeneic T-cells

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia (B-ALL)

Recruiting—posted June 21, 2016; updated October 25, 2019

Institut de recherches internationales servier

USA, UK, Belgium, France, Spain

NCT02808442

Dose escalation study of UCART19 in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (CALM)

I

Allogeneic T-cells

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia (B-ALL)

Recruiting—posted April 21, 2016; updated October 25, 2019

Institut de Recherches Internationales Servier

USA, UK, France, Japan

NCT02746952

A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19/ALLO-501

I

Allogeneic T-cells

Patients with advanced lymphoid malignancies dosed with UCART19/ALLO-501 (long-term safety evaluation)

Enrolling by invitation—posted April 12, 2016; updated January 7, 2020

Institut de Recherches Internationales Servier

USA, Belgium, France, Spain, UK

NCT02735083

Safety and efficacy of ALLO-501 anti-CD19 allogeneic CAR T cells in adults with relapsed/refractory large B cell or follicular lymphoma (ALPHA)

I/II

Allogeneic T-cells

Relapsed or refractory CD19 positive large B-cell lymphoma or follicular lymphoma patients

Recruiting—posted May 6, 2019; updated January 13, 2020

Allogene Therapeutics

USA

NCT03939026

Study evaluating safety and efficacy of UCART123 in patients with acute myeloid leukemia (AMELI-01)

I

Allogeneic T-cells

Patients with CD123 expressing relapsed/refractory AML patients, and in poor-prognosis, newly diagnosed AML patients in the European LeukemiaNet (ELN) adverse genetic risk group

Recruiting—posted June 16, 2017; updated December 6, 2019

Cellectis S.A.

USA

NCT03190278

Safety and efficacy of ALLO-715 BCMA allogenic CAR T cells in in adults with relapsed or refractory multiple myeloma (UNIVERSAL) (UNIVERSAL)

I

Allogeneic T-cells

Patients with relapsed or refractory multiple myeloma (MM) refractory to at least three prior lines of MM therapy

Recruting—posted September 18, 2019; updated December 12, 2019

Allogene Therapeutics

USA

NCT04093596

Phase I study of UCART22 in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (BALLI-01)

I

Allogeneic T-cells

Patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukaemia (B-ALL)

Recruiting—posted November 4, 2019

Cellectis S.A

USA

NCT04150497

Study evaluating safety and efficacy of UCART targeting CS1 in patients with relapsed/refractory multiple myeloma (MELANI-01)

I

Allogeneic T-cells

Patients with relapsed or refractory multiple myeloma (MM)

Recruiting—posted October 29, 2019; updated November 27, 2019

Cellectis S.A

USA

NCT04142619